Drugs / Zenagamtide
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07668401 | Jan 2027 → Jan 2029 expected | obesity disorder | Novo Nordisk A/S | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07668414 | Sep 2026 → Oct 2028 expected | obesity disorder | Novo Nordisk A/S | Not yet recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-05 | Novo Nordisk A/S | Novo Nordisk’s investigational zenagamtide shows significant HbA1C reductions with up to 14.6% weight loss in adults with type 2 diabetes - presented at ADA 2026 novonordisk.com ↗ |
| 2026-05-27 | Novo Nordisk A/S | Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association’s 2026 Scientific Sessions novonordisk.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zenagamtide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07668414 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT07668401 ↗ |